Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833898 | 0.94 | ACMSD (0.45) | ACMSDPTGS2HDAC1HDAC2HDAC3 | |
| SCHEMBL6047065 | 0.83 | CYP2A6 (0.42) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10793933 | 0.82 | ACMSD (0.53) | ACMSDPTGS2HDAC1HDAC2HDAC3 | |
| SCHEMBL10492496 | 0.80 | ALDH1A1 (0.44) | ACMSDPTGS2HDAC1HDAC2HDAC3 | |
| SCHEMBL676294 | 0.78 | ACMSD (0.41) | ACMSDPTGS2HDAC1HDAC2HDAC3 | |
| SCHEMBL10829816 | 0.77 | ACMSD (0.41) | ACMSDPTGS2HDAC1HDAC2HDAC3 | |
| SCHEMBL10829814 | 0.76 | ACMSD (0.40) | ACMSDPTGS2HDAC1HDAC2HDAC3 | |
| SCHEMBL11826170 | 0.75 | ACMSD (0.50) | ACMSDHDAC1HDAC2HDAC3ALDH1A1 | |
| SCHEMBL11826169 | 0.75 | ACMSD (0.50) | ACMSDHDAC1HDAC2HDAC3ALDH1A1 | |
| SCHEMBL4175163 | 0.74 | ACMSD (0.43) | ACMSDHDAC1HDAC2HDAC3TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | claimed |
| US-4345072-A | Process for the production of 5-arylidene hydantoins (B) | DEGUSSA AG (DE) | 1982-08-17 | — | — | US | claimed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-1463715-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| US-4613691-A | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0078768-B1 | PROCESS FOR THE CATALYTIC PD ARYLATION OF OLEFINES WITH ARYL HALOGENIDES | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0177072-A2 | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
| US-4564479-A | PALLADIUM COMPOUND, PHOSPHORUS OR ARSENIC COMPOUND | CIBA-GEIGY CORPORATION (US) | 1986-01-14 | — | — | US | disclosed |
| EP-0078768-A1 | Process for the catalytic Pd arylation of olefines with aryl halogenides | CIBA-GEIGY AG (CH) | 1983-05-11 | — | — | EP | disclosed |
| US-4345072-A | Process for the production of 5-arylidene hydantoins (B) | DEGUSSA AG (DE) | 1982-08-17 | — | — | US | disclosed |
| US-3966801-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3944589-A | α-Cycloalkenylphenyl-fatty acid nitriles | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | ACMSD 4128/4885PTGS2 2660/4885HDAC1 2649/4885 |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | ACMSD 4831/4885PTGS2 336/4885HDAC1 1197/4885 |
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | ACMSD 3881/4885PTGS2 3102/4885HDAC1 3499/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | ACMSD 4789/4885PTGS2 301/4885HDAC1 1365/4885 |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | ACMSD 1283/4885PTGS2 3479/4885HDAC1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.